Zepbound KwikPen listed as newest presentation in updated FDA approval history
The KwikPen joins three other Zepbound injection formats, offering another way to deliver the same tirzepatide doses, though pricing and insurance details were not listed.
Drugs.com's Zepbound approval history, last updated Feb 24, 2026, now lists the multi-dose KwikPen as the newest presentation of the brand [1]. The page's development timeline carries an approval entry dated Feb 23, 2026 titled "Zepbound (tirzepatide) Now Available in Multi-Dose KwikPen" [1].
Zepbound is Eli Lilly's brand of tirzepatide, a GIP and GLP-1 receptor agonist first approved by the FDA on Nov 8, 2023 for chronic weight management [1]. It is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity [1]. Tirzepatide was first approved in May 2022 under the brand name Mounjaro for type 2 diabetes [1].
What the updated listing shows
The approval history now lists four injection presentations: single-dose pen, single-dose vial, multi-dose vial, and the KwikPen, which the page describes as single-patient-use [1]. All six strengths appear in each: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg [1].
The single-dose pen and single-dose vial are listed at 0.5 mL per dose, from 2.5 mg/0.5 mL through 15 mg/0.5 mL [1]. The multi-dose vial and the KwikPen are listed as 2.4 mL devices holding four 0.6 mL doses each: 10 mg/2.4 mL for four 2.5 mg doses, 20 mg/2.4 mL for four 5 mg doses, 30 mg/2.4 mL for four 7.5 mg doses, 40 mg/2.4 mL for four 10 mg doses, 50 mg/2.4 mL for four 12.5 mg doses, and 60 mg/2.4 mL for four 15 mg doses [1].
Zepbound is given as a once-weekly subcutaneous injection into the abdomen, thigh or upper arm [1]. The page does not state a price for the KwikPen, whether it replaces any existing presentation, or when it will reach pharmacies beyond the Feb 23 availability entry [1].
Why it matters for patients
Zepbound is already sold in single-dose pens, single-dose vials and multi-dose vials, and the KwikPen adds a fourth option rather than replacing the others [1]. For someone already on tirzepatide, the practical difference is the device, not the drug: each listed multi-dose device holds four weekly doses, so refill frequency and packaging differ from single-dose formats [1]. The page does not describe how the KwikPen is handled, whether it requires different storage, or whether training is needed, so those details have not been reported.
Cost and coverage are often the deciding factor. The approval history lists no pricing, no insurance information and no self-pay details for the KwikPen [1]. Lilly previously released Zepbound single-dose vials and later offered all approved doses of the single-dose vials through LillyDirect self-pay pharmacy solutions, according to the same timeline [1]. No comparable announcement for the KwikPen appears on this page [1].
The page also restates limits and safety information that apply regardless of device. Coadministration of Zepbound with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended [1]. Zepbound carries a boxed warning for the risk of thyroid C-cell tumors [1]. Warnings and precautions include severe gastrointestinal reactions, acute kidney injury, acute gallbladder disease, acute pancreatitis, serious hypersensitivity reactions, increased risk of low blood sugar when used with insulin or an insulin secretagogue, diabetic retinopathy complications in people with type 2 diabetes, suicidal behavior and ideation, and pulmonary aspiration during general anesthesia or deep sedation [1]. Common side effects listed include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, belching, hair loss and heartburn [1].
In the trials cited on the page, adults taking the 15 mg dose in SURMOUNT-1 lost an average of 48 pounds, and those taking 5 mg lost an average of 34 pounds, compared with 7 pounds on placebo [1]. In SURMOUNT-2, average reductions were 15.7% (34.4 pounds) at 15 mg and 13.4% (29.8 pounds) at 10 mg, compared with 3.3% (7.0 pounds) on placebo [1].
What happens next
No dated milestones beyond the Feb 23, 2026 availability entry for the KwikPen appear on the approval history page [1]. Pricing, insurance coverage, pharmacy rollout and any changes to how the drug is dispensed have not been disclosed there [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.